Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers

International Journal of Cancer

Volumn 114, Issue 3, 2005, Pages 400-405

  Divine, Kevin K ^a   Pulling, Leah C ^a   Marron Terada, Patricia G ^a   Liechty, Kieu C ^a   Kang, Terri ^b   Schwartz, Ann G ^c   Bocklage, Therese J ^d   Coons, Teresa A ^e   Gilliland, Frank D ^b   Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e St Mary's Hospital Grand Junction   (United States)

Author keywords

DAPK; K ras; p16; Promoter hypermethylation; RASSF1A

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; K RAS PROTEIN; ONCOPROTEIN; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TOBACCO SMOKE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SIMILARITY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METHYLATION; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; STATISTICAL SIGNIFICANCE; URANIUM MINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINING; PREVALENCE; PROMOTER REGIONS (GENETICS); RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEINS;

EID: 20044383744     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20761     Document Type: Article

References (44)

1. Weist JS, Franklin WA, Drabkin H, Gemmill R, Sidransky D, Anderson MW. Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. J Cell Biochem 1997;28-9(Suppl):64-73.
2. Gazdar AF, Minna JD. Cigarettes, sex, and lung adenocarcinoma. J Natl Cancer Inst 1997;89:1563-5.
3. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer (Phila.) 1995;75:191-202.
4. Powell CA, Spira A, Derti A, DeLisi C, Liu G, Borczuk A, Busch S, Sahasrabudhe S, Cherr Y, Sugarbaker D, Bueno R, Richards WG, et al. Gene expression in lung adenocarcinomas of smokers and non-smokers. Am J Respir Cell Mol Biol 2003;29:157-62.
5. Lubin JH, Boice JD Jr, Edling C, Hornung RW, Howe GR, Kunz E, Kusiak RA, Morrison HI, Radford EP, Samet JM. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J Natl Cancer Inst 1995;87:817-27.
6. Powell CA, Bueno R, Borczuk A, Caracta Richards WG, Sugarbaker D, Brody JS. Patterns of allelic loss differ in lung adenocarcinomas of smokers and non-smokers. Lung Cancer 2003;39:23-9.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
8. INK4a and histological-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
9. Jarmalaith S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003;106:913-8.
10. Tang X, Khuri FR, Lee JL, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6.
11. Kim D, Nelson HH, Weincke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT. Promoter methylation of DAP-kinase: association with advanced stage in non-small lung cancer. Oncogene 2001;20:1765-70.
12. Dammann R, Schagdarsurengin U, Strunnikov M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003;18:665-77.
13. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
14. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5.
15. INK4A hypermethylation detected by fluorescence methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002;8:3782-7.
16. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7.
17. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margeli M, Sanchez JJ, Astudillo J, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non small-cell lung cancer patients. Cancer Lett 2003;193:207-16.
18. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
19. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Kazunori T, Sugio K, Shimizu N, Shimizu K, et al. Smoke exposure, histologic type and geographic-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
20. Belinsky SA, Klinge DM, Liechty KC, March TH, Kang T, Gilliland FD, Sotnic N, Adamova G, Rusinova G, Telnov V. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 2004;25:1063-7.
21. Tomizawa Y, Kohno T, Kondo H, Otsuka T, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-8.
22. Kim D, Kim JS, Ji Y, Shim YM, Kim H, Han J, Park J. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003;63:3743-6.
23. Chen JT, Chen YC, Wang YC, Tseng RC, Chen CY, Wang YC. Alterations of the p16 gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int J Cancer 2002;98:724-31.
24. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
25. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner, JF, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
26. 6- methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 2003;63:4842-8.
27. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF. Epigenetic down-regulation of death associated protein kinase in lung cancers. Clin Cancer Res 2003;9:3034-41.
28. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, Shim YM, Han J, Park J. Relationship of ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 2003;63:6206-11.
29. Sanchez-Cespedes M, Decker PA, Doffek KM, Estelle M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 2001;61:2092-6.
30. Brownson RC, Figgs LW, Caisley LE. Epidemiology of environmental tobacco smoke exposure. Oncogene 2002;21:7341-8.
31. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996;56:3655-8.
32. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
33. Denissenko MF, Pao A, Tang M-S, Pfeifer GP. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-2.
34. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
35. Gerde P, Muggenburg BA, Stephens T, Lewis JL, Pyon KH, Dahl AR. A relevant dose of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is extensively metabolized and rapidly absorbed in the canine tracheal mucosa. Cancer Res 1997;58:1417-22.
36. Gerde P, Muggenburg BA, Thornton-Manning JR, Lewis JL, Pyon KH, Dahl AR. Benzo[a]pyrene at an environmentally relevant dose is slowly absorbed by, and extensively metabolized in, tracheal epithelium. Carcinogenesis 1997;18:1825-32.
37. Gerde P, Medinsky MA, Bond JA. The retention of polycyclic aromatic hydrocarbons in the bronchial airways and in the alveolar region - a theoretical comparison. Toxicol Appl Pharmacol 1991;107:239-52.
38. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992;7:171-80.
39. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJA, Slebos RJC. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:2224-8.
40. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
41. Endoh H, Yatab, Y, Shimizu S, Tajima K, Kuwano H, Takahashi T. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 2003;106:45-51.
42. Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, Lo DYM, Yim APC. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 2002;79:101-6.
43. Niklinska W, Chyczewski L, Laudansk J, Chyczewska E, Niklinski J. Detection of p16 abnormalities in early-stage non-small cell lung cancer. Folia Histochem Cytobiol 2001;39(Suppl 2):30-2.
44. INK4b genes in non-small cell lung cancer. Int J Oncol 2001;19:277-81.